2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Computational Biology, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Gene Therapy, Non-Biological Therapies, Women’s Health, Adverse Events, Artificial Intelligence (AI), Biological Processes, Pathogenesis, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2955 Neurocognitive outcomes following erythropoietin therapy in adults with sickle cell disease: Results from the achieve-SCD pilot study

Nelly Kageha Kiriza, MD, MPH, Samyuktha Arunkumar2, Feyisayo T. Oluwole3, Shidhartho Roy, BS, MS4, Nahom Mossazghi, MS5, Lara Abdelmohsen6, Manzoor Mohideen, PhD7, Chigozie Ezebue8, Adeniyi Adiat9, Laura M. DeCastro, MD10, Enrico M Novelli, MD11, Titilope Adeyemo, MBBS, MSc, FMCPath12, Sossena Wood, PhD, BSc13, Julia Z Xu, MD, MScGH14, Olubusola Oluwole, MD15
1 Academic research Center for Hematology, Pittsburgh, Pennsylvania, United States, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
2 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
3 College of medicine, University of Lagos, Lagos, Lagos, Nigeria
4 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
5 Carnegie Mellon university, Pittsburgh, Pennsylvania, United States
6 Carnegie Mellon university, Pittsburgh, Pennsylvania, United States
7 Academic research Center for Hematology, Pittsburgh, Pennsylvania, United States, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
8 College of medicine, University of Lagos, Lagos, Lagos, Nigeria
9 Lagos University Teaching Hospital, Lagos, Lagos, Nigeria
10 Academic research Center for Hematology, Pittsburgh, Pennsylvania, United States, University of Pittsburgh, Pittsburgh, Pennsylvania, United States, Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
11 Division of Hematology/Medical oncology, University of Maryland, Baltimore, Maryland, United States
12 College of medicine, University of Lagos (CMUL), Lagos, Lagos, Nigeria, Lagos University Teaching Hospital, Lagos, Lagos, Nigeria
13 Carnegie Mellon university, Pittsburgh, Pennsylvania, United States
14 Academic research Center for Hematology, Pittsburgh, Pennsylvania, United States, University of Pittsburgh, Pittsburgh, Pennsylvania, United States, Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
15 Academic research Center for Hematology, Pittsburgh, Pennsylvania, United States, Division of Hematology/Medical oncology, University of Maryland, Baltimore, Maryland, United States, Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States, University of Pittsburgh, Pittsburgh, Pennsylvania, United States, Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Background

Neurocognitive impairment is a common complication in adults with sickle cell anemia (SCA) and affects various cognitive domains including processing speed, attention, memory and executive function. Chronic anemia, cerebral hypoxia and cumulative cerebrovascular injury contribute  to the development of cognitive impairment in SCA. Recombinant human erythropoietin (EPO) therapy increases hemoglobin (Hb) concentration and may improve cerebral oxygen delivery. Beyond its erythropoietic effects, growing experimental and clinical literature suggests that EPO may also have exert neuroprotective effects independent of erythropoiesis. However, whether exogenous EPO is associated with improved cognitive functioning in SCD is unknown. We evaluated the relationship between longitudinal changes in Hb, tissue oxygenation, and neurocognitive functioning following initiation of EPO therapy in patients with SCA.

Methods: ACHiEvE-SCD is a longitudinal pilot study of EPO treatment in adults with SCD (NCT05451940). Patients were treated with EPO per protocol for 12 weeks, after which they resumed routine clinical care; most patients discontinued EPO between weeks 12 and 24 due to lack of affordability. Laboratory and neurocognitive assessments were obtained at baseline, end of treatment (EOT; 12 weeks), and end of study (EOS; 24 weeks). All participants (n=17) were on hydroxyurea at baseline and continued throughout the study. Near-infrared spectroscopy (Portalite, Artinis) was used to measure resting tissue oxygenation in the forearm (forearm StO2) and in the prefrontal cortex (cerebral StO2). Neurocognitive function was assessed using five tasks of the NIH Toolbox Cognitive Battery: Dimensional Change Card Sort (measure of executive function), Flanker Inhibitory Control (executive function/attention), Picture Sequence (episodic memory), Pattern Comparison (processing speed), and List Sorting (working Memory). Age-adjusted standardized scores of each test were summed to derive the Fluid Cognitive Composite score. Given the small sample size and non-normal outcome distributions, changes across visits were evaluated using Friedman tests with multiplicity-adjusted pairwise comparisons. Associations between changes in Hb level and cognitive scores were assessed using Pearson and Spearman correlations. StO2 trajectories were explored using Python.

Results: Fifteen participants completed neurocognitive assessments; mean age was 28.7 ± 9.2 years, 9 (60%) were female. Median baseline EPO level was 111.3 mIU/mL (interquartile range, 66.6–186.0). Mean Hb showed a clear treatment response increasing from 7.5±1.2 g/dL at baseline to 10.6±1.2 g/dL at EOT (p<0.001) and then declining to 8.6±1.6 g/dL at EOS while remaining higher than baseline (p=0.006). Cerebral StO2 showed a borderline increase by 3.88% from baseline at EOT (n=9; 95% CI +0.75 to +7.31; p=0.052) and a non-significant change from baseline to EOS of +3.46 points (95% CI −0.09 to +7.34; p=0.152). Forearm STO2 did not show a significant treatment-related change at EOT or EOS. Fluid Cognitive Composite score increased from baseline (95.8±15.5) to 102.0±17.0 at EOT and 101.5±14.4 at EOS, but the overall change across all visits was not statistically significant (n=9; p=0.074).  Processing speed changed across the visits (41.6± 9.5 to 48.1±7.5 to 46.9±7.4; p=0.034), although adjusted pairwise comparisons were not significant. A greater increase in Hb level from baseline to the EOT was associated with greater improvement in processing speed (Spearman ρ=0.63, p=0.022). Episodic memory scores also changed across visits (n=12, p=0.039) with improved scores from baseline to EOT (p=0.048) but no difference at EOS. No significant longitudinal changes were observed in executive function, inhibitory control, or working memory. Changes in these measures were not significantly associated with changes in Hb and stO2.

Conclusion: EPO treatment produced a significant increase in Hb. Processing speed and episodic memory also improved over time, whereas overall fluid cognitive composite, executive function, attention, and working memory did not change significantly. The association between increased Hb and improved processing speed suggests that EPO may support cognitive processing efficiency. Larger controlled studies are needed to distinguish direct effects of EPO from those mediated through increased Hb and improved cerebral oxygen delivery.

Nelly Kageha Kiriza, MD, MPH: No relevant conflicts of interest to declare.